Shares of ValiRx plc (LON:VAL – Get Free Report) were up 24.8% during trading on Tuesday . The company traded as high as GBX 0.80 ($0.01) and last traded at GBX 0.78 ($0.01). Approximately 6,398,107 shares were traded during mid-day trading, an increase of 353% from the average daily volume of 1,411,171 shares. The stock had previously closed at GBX 0.63 ($0.01).
ValiRx Price Performance
The company has a quick ratio of 1.27, a current ratio of 6.65 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of £1.05 million, a price-to-earnings ratio of -39.65 and a beta of 0.59. The business’s 50 day simple moving average is GBX 1.29 and its 200-day simple moving average is GBX 1.90.
ValiRx Company Profile
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Further Reading
- Five stocks we like better than ValiRx
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Work and Play: Investing in the Rise of Bleisure Travel
- The 3 Best Retail Stocks to Shop for in August
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- What is MarketRank™? How to Use it
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for ValiRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx and related companies with MarketBeat.com's FREE daily email newsletter.
